Expert interchange breaking down topics in disease management with a focus on value, equitable care, health policy, and more.
June 27th 2023Biosimilars Stakeholder Summit: Interchangeable Biosimilars in Inflammatory Diseases
A panel of experts provide an overview of the clinical, economic, and humanistic burden of inflammatory conditions in the US, discuss the role of biologics and biosimilars in disease management and practical considerations for drug selection, define interchangeable biosimilars and discuss the potential value of these agents to patients, payers, and providers in the treatment of inflammatory diseases.
December 13th 2022Preventing Clinical Inertia in Early Treatment Management of Type 2 Diabetes
The information discussed in this series is a consensus from the Diabetes Cardiorenal & Metabolism Institute (DCMi) think Tank, a workshop consisting of 17 medical experts to create treatment consensuses based on data and expert opinion, for patients with complex multimorbid diseases plateauing or worsening in outcomes despite the emergence of numerous therapeutic options available. The DCMi will soon have a published consensus paper on early intervention and intensive management of the patient with diabetes and cardio-renal-metabolic diseases which compliments the DCRM multi-specialty practice accommodations.